Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 232

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Safety and Immunogenicity of the Quadrivalent Human Papillomavirus Vaccine in HIV‐1–Infected Men

Open access
Wilkin, Timothy, Lee, Jeannette Y., Lensing, Shelly Y., Stier, Elizabeth A., Goldstone, Stephen E., Berry, J. Michael, Jay, Naomi, Aboulafia, David, Cohn, David L., Einstein, Mark H., Saah, Alfred, Mitsuyasu, Ronald T., Palefsky, Joel M. · 2010 · The Journal of Infectious Diseases

Abstract

BACKGROUND: Human immunodeficiency virus type 1 (HIV-1)-infected men are at increased risk for anal cancer. Human papillomavirus (HPV) vaccination may prevent anal cancer caused by vaccine types. METHODS: AIDS Malignancy Consortium Protocol 052 is a single-arm, open-label, multicenter clinical trial to assess the safety and immunogenicity of the quadrivalent HPV (types 6, 11, 16, and 18) vaccine in HIV-1-infected men. Men with high-grade anal intraepithelial neoplasia or anal cancer by history or by screening cytology or histology were excluded. Men received 0.5 mL intramuscularly at entry, week 8, and week 24. The primary end points were seroconversion to vaccine types at week 28, in men who were seronegative and without anal infection with the relevant HPV type at entry, and grade 3 or higher adverse events related to vaccination. RESULTS: There were no grade 3 or greater adverse events attributable to vaccination among the 109 men who received at least 1 vaccine dose. Seroconversion was observed for all 4 types: type 6 (59 [98%] of 60), type 11 (67 [99%] of 68), type 16 (62 [100%] of 62), and type 18 (74 [95%] of 78). No adverse effects on CD4 counts and plasma HIV-1 RNA levels were observed. CONCLUSIONS: The quadrivalent HPV vaccine appears safe and highly immunogenic in HIV-1-infected men. Efficacy studies in HIV-1-infected men are warranted. Clinical trials registration. NCT 00513526.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1086/656320

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 232

Metadata

Authors
Wilkin, T., Lee, J. Y., Lensing, S. Y., Stier, E. A., Goldstone, S. E., Berry, J. M., Jay, N., Aboulafia, D., Cohn, D. L., Einstein, M. H., Saah, A., Mitsuyasu, R. T., & Palefsky, J. M.
Venue
The Journal of Infectious Diseases
Published
2010-10-15
Volume
202
Issue
8
Pages
1246-1253
ISSN
  • 0022-1899 (ISSN-L)
  • 1537-6613
OpenAlex
W2114986710
Cited by
232
References
1
FWCI
12.79
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and Immunogenicity of the Quadrivalent Human Papillomavirus Vaccine in HIV‐1–Infected Men. https://app.cochat.ai/papers/10.1086/656320
The paper
Wilkin, T., Lee, J. Y., Lensing, S. Y., Stier, E. A., Goldstone, S. E., Berry, J. M., Jay, N., Aboulafia, D., Cohn, D. L., Einstein, M. H., Saah, A., Mitsuyasu, R. T., & Palefsky, J. M. (2010). Safety and Immunogenicity of the Quadrivalent Human Papillomavirus Vaccine in HIV‐1–Infected Men. The Journal of Infectious Diseases. https://doi.org/10.1086/656320

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.